Contribute Try STAT+ Today

Yet another inspection by the Food and Drug Administration underscores the difficulties that Pfizer (PFE) is having with a key plant that has been responsible for severe shortages of injectables and other drugs.

The problems at the McPherson, Kan., facility, which Pfizer inherited as part of its $16 billion acquisition of Hospira three years ago, include employees who lack training to manufacture, process, or package products; a failure to review unexplained discrepancies in batches of medicines; and inadequate procedures to prevent contamination, according to an agency inspection report last July and August and posted on the FDA web site on Thursday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.